Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fosun Pharmaceutical Buys Stake In Tongjitang Chinese Medicines

This article was originally published in PharmAsia News

Executive Summary

Fosun Enterprises, a subsidiary of Fosun Pharmaceutical, recently paid $7.42 million for 5.73 percent stake in Tongjitang Chinese Medicines. Fosun Pharmaceutical explained that the move was mainly for investment purposes; however, it does not discount keeping, increasing or selling the stock in future. Industry analysts think the deal may bring hope to Tongjitang, which has considered delisting from the New York Stock Exchange due to below-expectation performance since its listing in April 2007. (Click here for more - Chinese Language)

You may also be interested in...



Fosun Pharmaceutical Buys More Stake In Tongjitang Chinese Medicines

As at Nov. 17, Fosun Enterprises has purchased a total of 2.5 million American Depository Shares in Tongjitang Chinese Medicines with $9.145 million. This accounts for 7.41 percent of the 135.34 million ordinary shares issued by Tongjitang at the end of last year (PharmAsia News, Oct. 27, 2008). Fosun Enterprises claims its acquisition is for investment purposes. Tongjitang, a TCM manufacturer, has a leading drug that fills the traditional medicinal space for treating osteoporosis. As of last June, the firm's total assets stood at RMB 1.63 billion ($238.79 million), with net equity of RMB 1.23 billion $180.19 million). Its revenue and net profit for the first half of this year were RMB 225.39 million ($33.01 million) and RMB 19.76 million ($2.89 million), respectively. (Click here for more - Chinese Language)

China Preps For First COVID Vaccine Roll-Outs

Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers. 

QUOTED. 3 December. Jessica Schubel.

A proposed rule released last month by the US Department of Health and Human Services is the Trump administration’s “latest attempt to sabotage HHS programs,” wrote Jessica Schubel, a senior policy analyst for the Center on Budget and Policy Priorities. See what the policy expert said about it in her blog post here.

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel